Udcahep contains Ursodeoxycholic Acid. Udcahep uses:
Udcahep is indicated for the treatment of Cholestasis (Jaundice), Viral Hepatitis, Alcoholic Fatty Liver, Primary Billiary Cirrhosis (PBC), Primary Sclerosing Cholangitis (PSC), Dissolution of Gallstones and Non-Alcoholic Steato Hepatitis (NASH).
Ursodeoxycholic acid is used to reduce the cholesterol saturation of bile and to promote the dissolution of gallstones. The cholesterol saturation of bile is reduced by Ursodeoxycholic acid, allowing gradual solubilization of cholesterol gallstones. Cholesterol of secretion into bile is reduced and bile acid secretion rate is increased during Ursodeoxycholic acid treatment without a reduction in phospholipids.
|Therapeutic Class:||Anti-gallstones drugs: Bile Acids|
|Manufacturer:||LAURES PHARMACEUTICALS PVT LTD|
|Last Updated:||March 10, 2021 at 12:00 am|
Table Of contents
Udcahep contains Ursodeoxycholic Acid 300.0 Mg. Udcahep Dosage
Dissolution of Gall stones: 8-12 mg/kg/day either as single night time dose or in divided doses
PBC: 10-15 mg/kg/day in 2-4 divided doses
Acute Viral Hepatitis: 600 mg/day
Alcoholic Fatty Liver: 300 mg/day
PSC: 25-30 mg/kg/day
NASH: 13-15 mg/kg/day
Commonly reported side effects are nausea, vomiting, diarrhoea, gallstone opacilication, pruritus.
Udcahep is a naturally occurring bile acid used to treat different hepatobilliary disorders. The activity of Udcahep is achieved through a decrease in secretion of cholesterol in bile. Udcahep achieves this through a few mechanisms: it reduces cholesterol absorption, suppresses liver cholesterol synthesis and it does not inhibit bile acid synthesis.
Therefore, alters bile composition from supersaturated to unsaturated. Udcahep also promotes the formation of liquid cholesterol crystal complexes which enhance removal of the cholesterol from the gallbladder into the intestine to be expelled. Udcahep improves cholestatic liver diseases by-
- Protecting cholangiocytes against cytotoxicity of hydrophobic bile acids
- Stimulating hepatobilliary secretion
- Protecting hepatocytes against bile acid-induced apoptosis
Udcahep is completely absorbed in the upper intestine. Time to peak serum concentration varies from 30 to 150 minutes. The rate of absorption ranges from 60-80%. After absorption Udcahep enters the portal vein and undergoes extraction from portal blood by liver where it is conjugated with amino acid & that may be either glycine or taurine and then secreted into the hepatic bile ducts. Small quantities of Udcahep appear in the circulation and very small amounts are excreted into urine. The biologic half life of Udcahep ranges from 3.5-5.8 days.
It should be used cautiously in those with liver disease.
Udcahep should not be used with drugs, such as oestrogenic hormones, that increase bile cholesterol. Concomitant administration with bile-acid binding drugs including antacids, charcoal and cholestyramine should be avoided, since this may reduce the effectiveness of therapy with Ursodeoxycholic acid.
Pregnancy Lactation use
Pregnancy category B. No evidence of harm has been reported in pregnancy. It has been effectively used for the treatment of cholestasis of pregnancy during the last trimester without any side effects. Problems have not been documented in humans regarding breast feeding.
Non-functioning gall-bladder calcified and pigmented gallstones, inflammatory bowel disease.
Interaction with other Medicine
Store below 25° C. Protected from light and moisture. Keep the medicine out of the reach of children.
Udcahep Tablet price in India 277.95